Patient and treatment characteristics
| Characteristic . | N (%) . |
|---|---|
| Diagnosis | |
| No CNS involvement | 168 |
| CNS involvement | 28 |
| Histology | |
| DLBCL | 158 (81) |
| tFL | 17 (9) |
| PMBCL | 11 (6) |
| tMZL | 3 (1.5) |
| tCLL | 3 (1.5) |
| tHL | 2 (1) |
| Richter transformation | 1 (<1) |
| Burkitt | 1 (<1) |
| Only patients with CNS involvement | |
| Type of involvement | |
| Parenchymal involvement only | 16 (57) |
| Meningeal involvement only | 6 (21) |
| Parenchymal and meningeal involvement | 6 (21) |
| CAR T-cell product | |
| Axicabtagene ciloleucel | 14 (50) |
| Tisagenlecleucel | 14 (50) |
| Age | |
| Median (range) | 58 (33-79) y |
| Sex | |
| Male | 16 (57) |
| Female | 12 (43) |
| International Prognostic Index | |
| Median (range) | 3 (1-5) |
| Normal LDH at CAR-T | 13 (48) |
| Bridging | |
| No | 4 (14) |
| Yes | 24 (86) |
| Intrathecal therapy | 4 (14) |
| CNS irradiation | 3 (11) |
| Polatuzumab based | 5 (18) |
| Venetoclax/ibrutinib | 4 (14) |
| Gemcitabine-oxaliplatin | 2 (7) |
| Others | 6 (25) |
| Response to bridging | 10 (42) |
| Characteristic . | N (%) . |
|---|---|
| Diagnosis | |
| No CNS involvement | 168 |
| CNS involvement | 28 |
| Histology | |
| DLBCL | 158 (81) |
| tFL | 17 (9) |
| PMBCL | 11 (6) |
| tMZL | 3 (1.5) |
| tCLL | 3 (1.5) |
| tHL | 2 (1) |
| Richter transformation | 1 (<1) |
| Burkitt | 1 (<1) |
| Only patients with CNS involvement | |
| Type of involvement | |
| Parenchymal involvement only | 16 (57) |
| Meningeal involvement only | 6 (21) |
| Parenchymal and meningeal involvement | 6 (21) |
| CAR T-cell product | |
| Axicabtagene ciloleucel | 14 (50) |
| Tisagenlecleucel | 14 (50) |
| Age | |
| Median (range) | 58 (33-79) y |
| Sex | |
| Male | 16 (57) |
| Female | 12 (43) |
| International Prognostic Index | |
| Median (range) | 3 (1-5) |
| Normal LDH at CAR-T | 13 (48) |
| Bridging | |
| No | 4 (14) |
| Yes | 24 (86) |
| Intrathecal therapy | 4 (14) |
| CNS irradiation | 3 (11) |
| Polatuzumab based | 5 (18) |
| Venetoclax/ibrutinib | 4 (14) |
| Gemcitabine-oxaliplatin | 2 (7) |
| Others | 6 (25) |
| Response to bridging | 10 (42) |
DLBCL, diffuse large B-cell lymphoma; LDH, lactate dehydrogenase; PMBCL, primary mediastinal B-cell lymphoma; tCLL, transformed chronic lymphocytic leukemia; tFL, transformed follicular lymphoma; tHL, transformed hodgkin lymphoma; tMZL, transformed marginal zone lymphoma.